TMO
VENTE TOTALE: 40 550 titres (~24 212 864,50 $ US)
- Insiders
- CASPER MARC N
- Total bought
- —
- Total sold
- $24,212,864
- Last activity
- 2026-08-24
- Last synced
-
2026-08-30 10:16:45
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-06
TMO presents solid liquidity (85) and decent fundamental health (65), but the weak catalyst score (25) driven by a significant $24.2M insider sale from the CEO heavily undermines near-term conviction.
The first sentence of the analysis written for TMO on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 37.7% | 41.3% | 40.1% | 42.3% | 50.1% | |
| Ebit Margin | 19.5% | 20.3% | 18.2% | 19.1% | 23.9% | |
| Ebitda Margin | 25.7% | 27.5% | 26.1% | 26.6% | 30.5% | |
| Operating Profit Margin | 18.2% | 17.9% | 17.4% | 19.0% | 26.3% | |
| Pretax Profit Margin | 16.3% | 16.3% | 14.6% | 17.1% | 22.5% | |
| Continuous Operations Profit Margin | 15.1% | 14.8% | 13.9% | 15.5% | 19.7% | |
| Net Profit Margin | 15.1% | 14.8% | 14.0% | 15.5% | 19.7% | |
| Bottom Line Profit Margin | 15.0% | 14.8% | 14.0% | 15.5% | 19.7% | |
| Current Ratio | 1.890 | 1.660 | 1.755 | 1.483 | 1.497 | |
| Quick Ratio | 1.533 | 1.287 | 1.392 | 1.152 | 1.121 | |
| Solvency Ratio | 0.168 | 0.198 | 0.181 | 0.195 | 0.191 | |
| Cash Ratio | 0.649 | 0.301 | 0.577 | 0.501 | 0.333 | |
| Price To Earnings Ratio | 32.608 | 31.377 | 34.178 | 31.060 | 34.025 | |
| Price To Earnings Growth Ratio | 4.543 | 4.641 | -2.754 | -3.240 | 1.561 | |
| Forward Price To Earnings Growth Ratio | 4.543 | 4.641 | -2.754 | -3.240 | 1.561 | |
| Price To Earnings Diluted Ratio | 32.663 | 31.472 | 34.355 | 31.218 | 34.288 | |
| Price To Earnings Diluted Growth Ratio | 4.462 | 4.502 | -2.767 | -3.338 | 1.574 | |
| Price To Book Ratio | 4.079 | 4.008 | 4.384 | 4.909 | 6.445 | |
| Price To Sales Ratio | 4.890 | 4.635 | 4.781 | 4.806 | 6.705 | |
| Price To Free Cash Flow Ratio | 34.622 | 27.347 | 29.578 | 31.236 | 37.449 | |
| Price To Operating Cash Flow Ratio | 27.868 | 22.929 | 24.374 | 23.582 | 27.548 | |
| Debt To Assets Ratio | 0.357 | 0.337 | 0.369 | 0.371 | 0.382 | |
| Debt To Equity Ratio | 0.737 | 0.661 | 0.779 | 0.820 | 0.891 | |
| Debt To Capital Ratio | 0.424 | 0.398 | 0.438 | 0.451 | 0.471 | |
| Long Term Debt To Capital Ratio | 0.402 | 0.370 | 0.401 | 0.397 | 0.441 | |
| Financial Leverage Ratio | 2.066 | 1.963 | 2.112 | 2.209 | 2.332 | |
| Working Capital Turnover Ratio | 3.992 | 4.425 | 4.560 | 6.030 | 4.278 | |
| Operating Cash Flow Ratio | 0.515 | 0.650 | 0.600 | 0.538 | 0.710 | |
| Operating Cash Flow Sales Ratio | 0.175 | 0.202 | 0.196 | 0.204 | 0.243 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.805 | 0.838 | 0.824 | 0.755 | 0.736 | |
| Debt Service Coverage Ratio | 2.205 | 2.699 | 2.034 | 1.709 | 3.252 | |
| Interest Coverage Ratio | 5.715 | 4.632 | 4.994 | 11.742 | 19.250 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.213 | 3.502 | 2.171 | 1.565 | 3.405 | |
| Operating Cash Flow Coverage Ratio | 0.199 | 0.264 | 0.231 | 0.254 | 0.263 | |
| Capital Expenditure Coverage Ratio | 5.127 | 6.191 | 5.684 | 4.081 | 3.782 | |
| Dividend Paid And Capex Coverage Ratio | 3.618 | 4.371 | 4.199 | 3.393 | 3.270 | |
| Dividend Payout Ratio | 0.094 | 0.092 | 0.087 | 0.065 | 0.051 | |
| Enterprise Value Multiple | 21.577 | 19.278 | 20.833 | 20.383 | 24.626 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 37.7% | ▼-3.7% | ▼-4.7% |
| Ebit Margin | 19.5% | ▼-0.8% | ▼-0.7% |
| Ebitda Margin | 25.7% | ▼-1.8% | ▼-1.6% |
| Operating Profit Margin | 18.2% | ▲0.3% | ▼-1.6% |
| Pretax Profit Margin | 16.3% | -0.0% | ▼-1.1% |
| Continuous Operations Profit Margin | 15.1% | ▲0.3% | ▼-0.7% |
| Net Profit Margin | 15.1% | ▲0.4% | ▼-0.7% |
| Bottom Line Profit Margin | 15.0% | ▲0.3% | ▼-0.8% |
| Current Ratio | 1.890 | ▲0.230 | ▲0.233 |
| Quick Ratio | 1.533 | ▲0.246 | ▲0.236 |
| Solvency Ratio | 0.168 | ▼-0.031 | ▼-0.019 |
| Cash Ratio | 0.649 | ▲0.347 | ▲0.176 |
| Price To Earnings Ratio | 32.608 | ▲1.231 | ▼-0.042 |
| Price To Earnings Growth Ratio | 4.543 | ▼-0.098 | ▲3.593 |
| Forward Price To Earnings Growth Ratio | 4.543 | ▼-0.098 | ▲3.593 |
| Price To Earnings Diluted Ratio | 32.663 | ▲1.192 | ▼-0.136 |
| Price To Earnings Diluted Growth Ratio | 4.462 | ▼-0.040 | ▲3.575 |
| Price To Book Ratio | 4.080 | ▲0.072 | ▼-0.685 |
| Price To Sales Ratio | 4.890 | ▲0.255 | ▼-0.273 |
| Price To Free Cash Flow Ratio | 34.621 | ▲7.275 | ▲2.575 |
| Price To Operating Cash Flow Ratio | 27.868 | ▲4.939 | ▲2.608 |
| Debt To Assets Ratio | 0.357 | ▲0.020 | ▼-0.006 |
| Debt To Equity Ratio | 0.738 | ▲0.076 | ▼-0.040 |
| Debt To Capital Ratio | 0.424 | ▲0.026 | ▼-0.012 |
| Long Term Debt To Capital Ratio | 0.402 | ▲0.032 | ▼-0.000 |
| Financial Leverage Ratio | 2.066 | ▲0.103 | ▼-0.070 |
| Working Capital Turnover Ratio | 3.992 | ▼-0.433 | ▼-0.665 |
| Operating Cash Flow Ratio | 0.515 | ▼-0.135 | ▼-0.088 |
| Operating Cash Flow Sales Ratio | 0.175 | ▼-0.027 | ▼-0.029 |
| Free Cash Flow Operating Cash Flow Ratio | 0.805 | ▼-0.034 | ▲0.013 |
| Debt Service Coverage Ratio | 2.205 | ▼-0.494 | ▼-0.175 |
| Interest Coverage Ratio | 5.715 | ▲1.082 | ▼-3.552 |
| Short Term Operating Cash Flow Coverage Ratio | 2.213 | ▼-1.289 | ▼-0.358 |
| Operating Cash Flow Coverage Ratio | 0.199 | ▼-0.066 | ▼-0.043 |
| Capital Expenditure Coverage Ratio | 5.127 | ▼-1.064 | ▲0.154 |
| Dividend Paid And Capex Coverage Ratio | 3.618 | ▼-0.753 | ▼-0.152 |
| Dividend Payout Ratio | 0.094 | ▲0.002 | ▲0.016 |
| Enterprise Value Multiple | 21.577 | ▲2.299 | ▲0.238 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $217.87B | $198.73B | $204.88B | $215.87B | $262.89B | |
| Enterprise value | $247.41B | $227.48B | $233.23B | $243.42B | $294.75B | |
| EV / Sales | 5.55x | 5.30x | 5.44x | 5.42x | 7.52x | |
| EV / Op. cash flow | 31.65x | 26.25x | 27.75x | 26.59x | 30.89x | |
| EV / Free cash flow | 39.31x | 31.30x | 33.67x | 35.22x | 41.99x | |
| EV / EBITDA | 21.58x | 19.28x | 20.83x | 20.38x | 24.63x | |
| Net debt / EBITDA | 2.58x | 2.44x | 2.53x | 2.31x | 2.66x | |
| Current ratio | 1.89x | 1.66x | 1.75x | 1.48x | 1.50x | |
| Income quality | 1.16x | 1.37x | 1.40x | 1.31x | 1.24x | |
| Graham number | $239 | $220 | $206 | $212 | $214 | |
| Graham net-net | -$96 | -$85 | -$88 | -$88 | -$103 | |
| Tax burden | 92.7% | 90.6% | 96.1% | 90.7% | 87.4% | |
| Interest burden | 83.7% | 80.5% | 80.1% | 89.5% | 94.2% | |
| Working capital | $13.52B | $8.80B | $10.58B | $8.22B | $6.68B | |
| Invested capital | $89.28B | $80.99B | $82.27B | $77.77B | $78.61B | |
| Return on assets | 6.1% | 6.5% | 6.1% | 7.2% | 8.1% | |
| Operating ROA | 7.8% | 7.8% | 7.6% | 8.9% | 12.6% | |
| Return on tangible assets | 14.9% | 17.6% | 15.8% | 18.1% | 23.4% | |
| Return on equity | 12.6% | 12.8% | 12.8% | 15.8% | 18.9% | |
| Return on invested capital | 7.6% | 8.0% | 8.0% | 9.0% | 10.7% | |
| Return on capital employed | 8.5% | 9.1% | 8.8% | 10.6% | 12.6% | |
| Earnings yield | 3.1% | 3.2% | 2.9% | 3.2% | 2.9% | |
| Free cash flow yield | 2.9% | 3.7% | 3.4% | 3.2% | 2.7% | |
| Capex / Op. cash flow | 19.5% | 16.2% | 17.6% | 24.5% | 26.4% | |
| Capex / Depreciation | 54.9% | 45.0% | 43.4% | 66.3% | 97.3% | |
| Capex / Sales | 3.4% | 3.3% | 3.5% | 5.0% | 6.4% | |
| SG&A / Sales | 16.3% | 20.2% | 19.6% | 20.1% | 20.2% | |
| R&D / Sales | 3.1% | 3.2% | 3.1% | 3.3% | 3.6% | |
| Stock comp / Sales | 0.7% | 0.7% | 0.6% | 0.7% | 0.6% | |
| Intangibles / Total assets | 59.1% | 63.1% | 61.5% | 60.4% | 65.3% | |
| Days sales outstanding | 87d | 82d | 82d | 77d | 83d | |
| Days payables outstanding | 48d | 45d | 41d | 48d | 53d | |
| Operating cycle | 158d | 154d | 155d | 156d | 177d | |
| Cash conversion cycle | 110d | 109d | 114d | 108d | 124d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+9.6%EV / Sales ▲+4.7%EV / EBITDA ▲+11.9%EV / Op. cash flow ▲+5.399Earnings yield ▼-0.001Graham number ▲+19.221
Profitability
Return on equity ▼-0.002Return on assets ▼-0.004Return on invested capital ▼-0.004Return on capital employed ▼-0.006Operating ROA -0.000Income quality ▼-0.204Tax burden ▲+0.021
Efficiency
Days sales outstanding ▲+4.616Days payables outstanding ▲+2.909Operating cycle ▲+3.658Cash conversion cycle ▲+0.749Capex / Sales ▲+0.002R&D / Sales ▼-0.001
Balance-sheet strength
Current ratio ▲+0.230Net debt / EBITDA ▲+0.139Working capital ▲+4713000000.000Invested capital ▲+8297000000.000Intangibles / Total assets ▼-0.040
Change over 5 years
Valuation
Market cap ▼-17.1%EV / Sales ▼-26.1%EV / EBITDA ▼-12.4%EV / Op. cash flow ▲+0.759Earnings yield ▲+0.002Graham number ▲+25.580
Profitability
Return on equity ▼-0.063Return on assets ▼-0.020Return on invested capital ▼-0.031Return on capital employed ▼-0.041Operating ROA ▼-0.048Income quality ▼-0.072Tax burden ▲+0.053
Efficiency
Days sales outstanding ▲+3.290Days payables outstanding ▼-5.861Operating cycle ▼-19.598Cash conversion cycle ▼-13.737Capex / Sales ▼-0.030R&D / Sales ▼-0.005
Balance-sheet strength
Current ratio ▲+0.393Net debt / EBITDA ▼-0.086Working capital ▲+6841000000.000Invested capital ▲+10672000000.000Intangibles / Total assets ▼-0.062
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-10 | Dan Newhouse | Sale | $1,001 - $15,000 |
| 2026-05-07 | Dwight Evans | Sale (Partial) | $1,001 - $15,000 |
| 2026-04-13 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-03-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-23 | Valerie Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-09-12 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-19 | Kelly Louise Morrison | Sale | $15,001 - $50,000 |
| 2025-08-19 | Kelly Louise Morrison | Sale | $15,001 - $50,000 |
| 2025-08-19 | Kelly Louise Morrison | Sale | $1,001 - $15,000 |
| 2025-08-19 | Kelly Louise Morrison | Sale | $1,001 - $15,000 |
| 2025-08-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-30 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-07-25 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2025-07-22 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-06-10 | Lisa McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-06 | Valerie Hoyle | Purchase | $1,001 - $15,000 |
| 2025-05-16 | Richard W. Allen | Sale | $15,001 - $50,000 |
| 2025-05-15 | Rob Bresnahan | Purchase | $15,001 - $50,000 |
| 2025-05-05 | Thomas H. Kean | Purchase | $1,001 - $15,000 |
| 2025-04-28 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-04-21 | Bruce Westerman | Sale | $1,001 - $15,000 |
| 2025-04-11 | Dan Newhouse | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-11 | Richard W. Allen | Sale | $15,001 - $50,000 |
| 2025-04-08 | Rob Bresnahan | Sale | $15,001 - $50,000 |
| 2025-03-27 | Greg Landsman | Sale | $1,001 - $15,000 |
| 2025-03-03 | Valerie Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2024-12-12 | Michael Rulli | Sale | $1,001 - $15,000 |
| 2024-12-11 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Valerie Hoyle | Purchase | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-10 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-03-06 | John James | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-09 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2024-02-09 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-12-04 | John Curtis | Sale | $1,001 - $15,000 |
| 2023-11-28 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-27 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-10-27 | Michael McCaul | Sale | $15,001 - $50,000 |
| 2023-10-26 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-10-24 | Greg Stanton | Sale | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-02 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-07-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale | $50,001 - $100,000 |
| 2023-06-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-06-28 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-06-21 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2023-06-21 | Michael McCaul | Purchase | $15,001 - $50,000 |
| 2023-05-25 | Zoe Lofgren | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-05-23 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-05-19 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-05-02 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-05-02 | Michael McCaul | Purchase | $50,001 - $100,000 |
| 2023-03-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $1,001 - $15,000 |
| 2023-02-23 | John Curtis | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-31 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2023-01-11 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-12-05 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-11-30 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-11-03 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-10-12 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-07-22 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-07-22 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-07-15 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2022-06-27 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Sale | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-05-05 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-03-10 | Richard W. Allen | Purchase | $15,001 - $50,000 |
| 2022-03-08 | Dan Newhouse | Purchase | $1,001 - $15,000 |
| 2021-11-02 | Dan Newhouse | Purchase | $1,001 - $15,000 |
| 2021-04-12 | Richard W. Allen | Sale (Partial) | $15,001 - $50,000 |
| 2021-03-10 | Richard W. Allen | Purchase | $15,001 - $50,000 |
| 2021-01-25 | Richard W. Allen | Purchase | $15,001 - $50,000 |
Recent news
- 2026-08-29 37,709 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Beacon Pointe Advisors LLC Beacon Pointe Advisors LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE: TMO) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased 37,709 shares of the medical research company''s stock, valued at approximately $18,906,000. Several other hedge funds also recently modified their holdings of
- 2026-08-28 Ausdal Financial Partners Inc. Makes New $456,000 Investment in Thermo Fisher Scientific Inc. $TMO Ausdal Financial Partners Inc. bought a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 910 shares of the medical research company''s stock, valued at approximately $456,000. Several other hedge funds and other
- 2026-08-28 Bank OZK Takes $1.10 Million Position in Thermo Fisher Scientific Inc. $TMO Bank OZK purchased a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,186 shares of the medical research company''s stock, valued at approximately $1,096,000. A number of other
- 2026-08-27 Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ G2 Electron Detector to Advance Materials Research WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ EMPAD™ G2 detector, a new detector designed to help researchers see and understand materials in unprecedented detail. EMPAD G2 enables high-speed four-dimensional scanning transmission electron microscopy (4D STEM), an advanced form of electron microscopy that captures far more information about a material than a standard image, helping researchers better.
- 2026-08-26 Delta Air, Target, Thermo Fisher Scientific And A Financial Stock On CNBC''s ‘Final Trades'' On CNBC''s “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Delta Air Lines, Inc. (NYSE:DAL).
- 2026-08-25 Thermo Fisher Scientific Launches First Orbitrap Mass Spectrometers for Isotope Ratio Analysis, Enabling More Labs to Decode the Story Behind a Sample WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ Orbitrap™ Isora™ Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, the company''s first Orbitrap instruments with a dedicated isotope ratio analysis mode. Together with the Thermo Scientific™ Vanquish™ Duo UHPLC System and new Isotope Discoverer™ Software, the instruments form an integrated workflow designed to make molecular-level isotope ratio analys.
- 2026-08-24 Is TMO Overvalued? DCF Says Worth $491 On August 24, 2026, we conducted a DCF analysis for Thermo Fisher Scientific Inc (TMO) amidst a backdrop of strong price performance, with the stock up 30.6% ov
- 2026-08-22 Avanda Investment Management Pte. Ltd. Invests $2 Million in Thermo Fisher Scientific Inc. $TMO Avanda Investment Management Pte. Ltd. acquired a new position in Thermo Fisher Scientific Inc. (NYSE: TMO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 4,000 shares of the medical research company''s stock, valued at approximately $2,005,000. Thermo Fisher Scientific accounts for
- 2026-08-22 Allworth Financial LP Takes $12.20 Million Position in Thermo Fisher Scientific Inc. $TMO Allworth Financial LP bought a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 24,334 shares of the medical research company''s stock, valued at approximately $12,200,000. Several other hedge funds
- 2026-08-21 Bank of New York Mellon Corp Invests $1.97 Billion in Thermo Fisher Scientific Inc. $TMO Bank of New York Mellon Corp bought a new stake in Thermo Fisher Scientific Inc. (NYSE: TMO) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,938,410 shares of the medical research company''s stock, valued at approximately $1,974,561,000. Bank of New